Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.

Published: 2nd September 2019

Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.

Conclusion

This study included 3384 women followed for a median 7.5 years. The adjusted hazard ratio for disease-free survival for the 12 months versus the six months group was 1.08, 95 per cent confidence interval 0.93 to 1.25, P=0.39. The authors concluded non-inferiority of the six month course was not proven.

Pubmed Link

Your comments

0 Comments